Rare Case of Severe Pancreatitis Induced by Encorafenib and Cetuximab in BRAF V600E-Positive Colorectal Cancer
Doublet chemotherapy with encorafenib and cetuximab has demonstrated a survival benefit for BRAF V600E mutation-positive advanced colorectal cancer, which generally has a poor prognosis, as shown in the BEACON CRC trial. We encountered a case of rectal cancer with this mutation, complicated by grade 3 pancreatitis, one month after starting this doublet therapy. Despite aggressive treatment efforts, the pancreatitis led to duodenal ulcer perforation and a fatal intra-abdominal abscess. This case highlights pancreatitis as a rare, but severe, side effect of combination chemotherapy.
Authors
- Gota Fujisawa (ORCID: https://orcid.org/0000-0002-0218-200X)
- Narikazu Boku (ORCID: https://orcid.org/0000-0002-1438-707X)
- Chisaki Suzumori
- Yu Miyakawa
- Nobumi Suzuki (ORCID: https://orcid.org/0000-0001-9566-8828)
- Go Endo (ORCID: https://orcid.org/0000-0002-8334-5746)
- Mitsuhiro Fujishiro (ORCID: https://orcid.org/0000-0002-4074-1140)
- Yuki Ishigaki
- Yoku Hayakawa (ORCID: https://orcid.org/0000-0002-3988-2499)
- Takuma Iwata (ORCID: https://orcid.org/0000-0001-5229-3042)
- Takeshi Hayashi
- Kenji Tamada
Institutions
- Tokyo University of Science (JP)
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2025-04-28
- DOI
- https://doi.org/10.2169/internalmedicine.5389-25
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- University of Tokyo
- Japan Society for the Promotion of Science